Covid19 : Oxford University tests Ivermectin as possible treatment drug
The University of Oxford said on Wednesday it was testing anti-parasitic drug ivermectin as a possible treatment for Covid-19, as part of a British government-backed study that aims to aid recoveries in non-hospital settings.
Ivermectin is the seventh treatment to be investigated in the trial, and is currently being evaluated alongside antiviral drug favipiravir, the university said. People with severe liver conditions, who are on blood-thinning medication warfarin, or taking other treatments known to interact with ivermectin, will be excluded from the trial, the university added.
However, in a recent study, it was found that the oral antiparasitic drug can be used as a “prophylaxis treatment” against COVID-19 as its regular use could significantly reduce the risk of contracting coronavirus or at least prevents infection from taking a severe turn.
A German body, in its analysis of Ivermectin, identified that there is “no scientific basis for a potential therapeutic effect against COVID-19 from pre-clinical studies”. The Directorate General of Health Services under the Union Health Ministry decided to drop the medicine from the list of covid drugs as a cure for mild or asymptomatic cases.
While the World Health Organization, and European and US regulators have recommended against using ivermectin in Covid-19 patients, it is being used to treat the illness in some countries, including India.